Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis
Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, Mustacchia P
Therapeutic advances in gastroenterology · 62 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-07-20 · Ther Adv Gastroenterol · vol. 9 · número 1 · págs. 113–120
- Editorial
- SAGE Publishing
- Citado
- 109 citas · más que el 98% de estudios similares · 7.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 29 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Coffee research and impacts · Liver Disease Diagnosis and Treatment · Tea Polyphenols and Effects
- Palabras clave
- Medicine, Caffeine, Nonalcoholic fatty liver disease, Internal medicine, Meta-analysis, Gastroenterology, Confidence interval, Fatty liver, Subgroup analysis, Cirrhosis, Fibrosis, Hepatic fibrosis, Disease
7 autores
- Huafeng Shen🇺🇸Nassau University Medical Center
- Andrea C. Rodriguez🇺🇸University of South Florida
- Ashok Shiani🇺🇸University of South Florida
- Seth Lipka🇺🇸University of South Florida
- Ghulamullah Shahzad🇺🇸Nassau University Medical Center
- Ambuj Kumar🇺🇸University of South Florida
- Paul J. Mustacchia🇺🇸Nassau University Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
Caffeine consumption is reported to be associated with reduced hepatic fibrosis in patients with chronic liver diseases. We performed a systematic review and meta-analysis to assess the association between caffeine consumption and prevalence or hepatic fibrosis of nonalcoholic fatty liver disease (NAFLD) in observational studies.
Methods
We searched the literature of all languages from PubMed, EMBASE, and the Cochrane library from 1 January 1980 through 10 January 2015. Total caffeine consumption was defined as the daily intake of caffeine (mg/day) from all caffeine-containing products. Combined and subgroup analyses stratified by study designs, study locations, and type of caffeine intake were performed.
Results
Four cross-sectional and two case control studies with a total of 20,064 subjects were included in the meta-analysis. Among these, three studies with 18,990 subjects were included in the analysis for prevalence of NAFLD while the other three studies with 1074 subjects were for hepatic fibrosis. Total caffeine consumption (mg/day) was not significantly associated with either the prevalence [pooled mean difference (MD) 2.36; 95% confidence interval (CI) -35.92 to 40.64] or hepatic fibrosis (higher versus lower stages; pooled MD -39.95; 95% CI -132.72 to 52.82) of NAFLD. Subgroup analyses stratified by study designs and locations were also not significant. However, after stratifying by type of caffeine intake, regular coffee caffeine intake (mg/day) was significantly associated with reduced hepatic fibrosis of NAFLD (pooled MD -91.35; 95% CI -139.42 to -43.27; n = 2 studies).
Conclusion
Although total caffeine intake is not associated with the prevalence or hepatic fibrosis of NAFLD, regular coffee caffeine consumption may significantly reduce hepatic fibrosis in patients with NAFLD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.